Drawing on leading practitioner and academic insights, the following webinars are designed to inform and support the treatment and care of patients with chronic myeloid leukaemia (CML).

The Changing Management of CML webinar (2nd November 2021)

 

 

PUTTING NEW GUIDELINES INTO PRACTICE: DIAGNOSTICS & PROGNOSIS

Professor of Practice for Chronic Myeloid Malignancies at Hammersmith Hospital, Dragana Milojkovic, explores the value of diagnostic and prognostic scoring in CML as recommended in the 2020 ELN Guidelines.

 
 

BCR-ABL MONITORING & MUTATION TESTING IN 2021

Professor Nick Cross from the Salisbury Faculty of Medicine, University of Southampton, discusses research into the benefits and challenges associated with BCR-ABL monitoring and mutation testing.

 
 

PUTTING NEW GUIDELINES INTO PRACTICE: OPTIMISING PATIENT MANAGEMENT

Professor Dragana Milojkovic examines how to effectively use screening to identify mutations and treatment issues to optimise patient tyrosine kinase inhibitor treatment.

 

The Changing Role of the CNS in CML webinar (23rd November 2021)

 

 

MANAGEMENT OF CML PATIENTS IN 2021

Professor Mhairi Copland from the Institute of Cancer Sciences, University of Glasgow, looks at the changes to the ELN and BJH guidelines and how the management of CML has adapted since the outbreak of COVID-19.

 
 

ADAPTING THE CNS ROLE IN A CRISIS: KEY LESSONS LEARNT

Kirsty Crozier, Haematology APC at Great Western Hospital, Swindon, discusses how support and treatment management for patients with myeloid disorders has evolved in response to the COVID-19 crisis.

 

APC, activated protein C; BCR-ABL, breakpoint cluster region-abelson; BJH, British Journal of Haematology; CML, chronic myeloid leukaemia; CNS, clinical nurse specialist; ELN, European LeukemiaNet.

Rate this content: 
No votes yet
UK | February 2022 | 188508
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]